283. 後天性赤芽球癆 Acquired pure red cell aplasia Clinical trials / Disease details
臨床試験数 : 19 / 薬物数 : 36 - (DrugBank : 23) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04470804 (ClinicalTrials.gov) | July 1, 2020 | 9/7/2020 | Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA | Sirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective Study | Pure Red Cell Aplasia, Acquired | Drug: Sirolimus;Drug: Cyclosporine A | Bing Han | NULL | Completed | 18 Years | 88 Years | All | 56 | Phase 4 | China |
2 | NCT01288131 (ClinicalTrials.gov) | January 2009 | 1/2/2011 | Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment | Randomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and Prednisolone | Anti-r-HuEpo Associated PRCA Subjects | Drug: Cyclosporine combine with mycophenolate mofetil;Drug: Cyclophosphamide + pred | Chulalongkorn University | NULL | Terminated | 18 Years | 60 Years | Both | 8 | Phase 3 | Thailand |